Sunresin New Materials Co (300487) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
11 Aug, 2026Executive summary
Achieved record revenue of ¥2.55 billion, up 2.62% year-over-year; net profit attributable to shareholders reached ¥787 million, up 9.79% year-over-year.
Core business (excluding large lithium extraction projects) grew 24.7% year-over-year to ¥2.45 billion, accounting for 96.1% of total revenue.
Operating cash flow reached ¥731.8 million, up 9.34% year-over-year, supporting healthy business expansion.
Overseas sales surged 45.1% year-over-year to ¥655 million, with international business now 25.65% of total revenue.
Maintained strong R&D investment at ¥146 million, with 5 new domestic and 6 new international patents granted.
Financial highlights
Gross margin for separation materials was 52.85%, and for system equipment 31.05%.
Weighted average ROE was 21.33%, down 1.79 percentage points year-over-year.
Total assets grew 6.85% to ¥6.09 billion; net assets attributable to shareholders rose 13.89% to ¥3.91 billion.
Asset-liability ratio improved to 35.47% from 39.32% year-over-year.
Basic EPS was ¥1.56, diluted EPS ¥1.55.
Outlook and guidance
Focus on stable growth in core materials business and high-quality delivery of major projects, especially in Tibet.
Continued international expansion, with emphasis on localizing sales and technical support in key overseas markets.
Ongoing investment in R&D and talent to drive innovation and maintain industry leadership.
Commitment to ESG principles and sustainable, green manufacturing.
Latest events from Sunresin New Materials Co
- Record revenue and profit, robust segment growth, and strong international expansion.300487
Q2 2024 - Revenue and net profit rose double digits year-over-year, with robust cash flow and expansion.300487
Q3 2024 - Net profit rose 10% to ¥444.5 million on improved margins and strong cash flow.300487
Q2 2025 - Net profit up 14.18% year-over-year despite 8.58% revenue drop; cash flow surged.300487
Q1 2025 - Record revenue and profit growth driven by core segments and robust R&D investment.300487
Q4 2025 - Q3 saw double-digit revenue growth and new investment in a life sciences materials park.300487
Q3 2025 - Revenue up 5.24%, net profit down 5.81%, and operating cash flow up 36.59% year-over-year.300487
Q1 2026